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Abstract
Background: Cell cycle deregulation is common in human cancer, and alterations of p27 and p21, two critical cell
cycle regulators, have been implicated in the development of many human malignancies. Therefore, we
hypothesize that p27 T109G polymorphism individually or in combination with p21 (C98A and C70T)
polymorphisms modifies risk of second primary malignancy (SPM) in patients with index squamous cell carcinoma
of head and neck (SCCHN).
Methods: A cohort of 1,292 patients with index SCCHN was recruited between May 1995 and January 2007 at the
M.D. Anderson Cancer Center and followed for SPM occurrence. Patients were genotyped for the three
polymorphisms. A log-rank test and Cox proportional hazards models were used to compare SPM-free survival and
SPM risk.
Results: We found that patients with p27 109 TG/GG, p21 98 CA/AA and p21 70 CT/TT variant genotypes had a
worse SPM-free survival and an increased SPM risk than those with the corresponding p27109 TT, p21 98 CC, and
p21 70 CC common genotypes, respectively. After combining the three polymorphisms, there was a trend for
significantly increased SPM risk with increasing number of the variant genotypes (Ptrend = 0.0002). Moreover,
patients with the variant genotypes had an approximately 2.4-fold significantly increased risk for SPM compared
with those with no variant genotypes (HR, 2.4, 95% CI, 1.6-3.6).
Conclusions: These results suggest that p27 T109G polymorphism individually or in combination with p21 (C98A
and C70T) polymorphisms increases risk of SPM in patients with index SCCHN.
Keywords: p21, p27, Squamous cell carcinoma of head and neck, Second primary malignancy, Genetic susceptibil-
ity, Polymorphism
Introduction
In the United States, squamous cell carcinoma of the
head and neck (SCCHN) accounts for approximately
50,000 new cancer cases, causing 11,480 deaths annually
[1,2]. SCCHN has modest survival rates mainly because
of second primary malignancies (SPM), comorbid
illnesses, and index cancer recurrence [3]. A leading
cause of mortality in such patients is the development of
SPM [3]. Additional studies on host factors that predict
SPM in SCCHN patients are needed so that intensive
surveillance or targeted intervention for patients at high-
risk of SPM may improve prognosis. In addition to smok-
ing, alcohol drinking and cancer treatment as risk factors
for SPM, genetic predisposition might also influence the
development of SPM after index SCCHN [3-10].
A common feature of human cancer is cell cycle
deregulation, and cell cycle progression is governed by
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(CDKs), which function together in the G1 phase to
initiate S phase and in G2 to initiate mitosis. Through
regulation of cyclin-CDK complexes, p27 and p21, two
critical CDK inhibitors, act as a fail-safe mechanism
involved in DNA repair and apoptosis [11]. Further-
more, p21 can inhibit CDK activity not only individually
but also in combination with p27 to increase cellular
levels of this inhibition [12]. Therefore, both p27 and
p21 may serve as universal CDK inhibitors and play
active roles in the development of SPM, because these
two proteins have similar biological activities in the reg-
ulation of cell cycle control, DNA repair, and apoptosis.
Several molecular epidemiological studies have exam-
ined associations of common single nucleotide poly-
morphisms (SNPs) in p21and p27 with risk of various
cancers, including SCCHN [13-17]. These SNPs include
p21 C98A (a non-synonymous serine-to-arginine substi-
tution at codon 31), p21 C70T (a single C-to-T substitu-
tion 20 nt downstream of the stop codon at exon 3),
and p27 T109G (a T-to-G change at codon 109 result-
ing in an amino acid substitution of valine for glycine).
The two polymorphisms of p21 have been previously
reported to significantly modify risk of SPM after index
SCCHN [18], but no such studies have been done for
the p27 polymorphism. Moreover, because both p21 and
p27 are involved in the same cell cycle regulation path-
way and bind to cyclin D1-CDK complexes to inhibit
their catalytic activity and induce cell-cycle arrest, they
may have redundant or synergistic effect on cell cycle
inhibition. However, there is no published study that
has assessed, simultaneously, above three putatively
functional SNPs in SPM. Thus, given the crucial roles of
both p27 and p21 in cell cycle regulation, we hypothe-
size that p27 (T109G) polymorphism individually or in
combination with p21 (C98A and C70T) polymorphisms
modifies risk for SPM after index SCCHN, and we
tested this hypothesis in a cohort of 1,292 SCCHN
patients.
Results
This was a relatively large and well-characterized cohort
of 1,292 SCCHN patients who were followed up for a
median follow-up time of 34 months (range 0 to 142.4
months), and the overall median follow-up time was
30.9 and 14.4 months for SPM-free patients and SPM
patients, respectively. Table 1 shows demographics,
tobacco smoking, alcohol drinking, and clinical variables
for the patients. Of the 120 SPM patients, 81 developed
SPMs at tobacco-related sites including 44 SCCHN
SPM and 37 other tobacco-related cancers (34 lung can-
cer, 2 esophagus cancer, and 1 bladder cancer), 35
developed SPMs at non-tobacco-related SPMs (10 pros-
tate cancer, 8 papillary thyroid carcinoma, 4 colon
adenocarcinoma, 3 lymphoma, 3 hepatic adenocarci-
noma, 2 breast cancer, and 1 each for the remainder
including sarcoma, renal cell carcinoma, endometrial
carcinoma, leukemia, and maxillary sinus adenocarci-
noma); and 4 developed SPMs at both tobacco-related
and non-tobacco-related sites ((2 patients with both
SCCHN and prostate cancer and 2 patients with both
SCCHN and papillary thyroid carcinoma).
In this cohort of SCCHN patients, the mean age at
diagnosis for the index SCCHN was 57.4 years (range,
18-94 years, median, 57 years), and the mean age of
index SCCHN patients who developed SPM was signifi-
cantly older than that of patients who were SPM-free
(60.8 years versus 57.1 years, respectively; P < 0.01). The
male patients (76.0%) were the majority of study
Table 1 Distribution of selected characteristics of the
patient cohort (n = 1,292)
Total SPM-Free SPM P-
values
c
Variable No. % No. % No. %
Total patients 1,292 100 1,172 100 120 100
Age
≤ median (57 years) 668 51.7 629 53.7 39 32.5 < 0.001
> median (57 years) 624 48.3 543 46.3 81 67.5
Sex
Male 981 75.9 887 75.7 94 78.3 0.518
Female 311 24.1 285 24.3 26 21.7
Ethnicity
Non-Hispanic White 1,093 84.6 999 85.2 94 78.3 0.050
Other 199 15.4 173 14.8 26 21.7
Smoking
Never 346 26.8 321 27.4 25 20.8 0.122
Ever 946 73.2 851 72.6 95 79.2
Alcohol
Never 337 26.1 310 26.4 27 22.5 0.348
Ever 955 73.9 862 73.6 93 77.5
Index Cancer Site
Oral cavity 420 32.5 382 32.6 38 31.7 0.320
Oropharynx 575 44.5 527 45.0 48 40.0
Larynx/Hypopharynx 297 23.0 263 22.4 34 28.3
Index Cancer Stage
I or II 327 25.3 295 25.0 32 26.7 0.720
III or IV 965 74.7 877 75.0 88 73.3
Treatment
Surgery only 230 17.8 209 17.8 21 17.5 0.894
Surgery + Adjuvant
Tx
a
322 24.9 289 24.7 33 27.5
XRT
b 330 25.6 302 25.8 28 23.3
XRT +
Chemotherapy
410 31.7 372 31.7 38 31.7
aAdjuvant Treatment: adjuvant radiotherapy and/or chemotherapy
bXRT: radiotherapy
cP values were calculated from chi-square test
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sex was associated with SPM development (P = 0.518).
In addition, no significant differences in characteristics
regarding smoking (P =0 . 1 2 2 ) ,a l c o h o ld r i n k i n g( P =
0.348), cancer site (P = 0.320), cancer stage (P =0 . 7 2 0 ) ,
or treatment (P = 0.894) were found between patients
who developed SPM and those who were SPM-free.
However, ethnicity was significantly different between
patients who were SPM-free and patients who developed
SPM, and the patients who were non-Hispanic whites
more likely developed a SPM than the patients who
were not non-Hispanic whites (P = 0.050).
The distributions of p27 T109G, p21 C98A, and p21
C70T genotypes between patients who developed SPM
and those who did not and their associations with risk
of SPM are presented in Table 2. p27 109 TG + GG
variant genotypes were common in patients who devel-
oped SPM (62.5%) as opposed to patients who were
SPM-free (43.6%), and these p27 109 G variant geno-
types were associated with a 2-fold significantly
increased risk of SPM compared with the p27 109 TT
common homozygous genotype (HR, 2.0; 95% CI, 1.5-
3 . 1 ) .A sw eh a v ep r e v i o u s l yr e p o r t e d ,t h ev a r i a n tg e n o -
types of the two p21 polymorphisms were significantly
associated with increased risk of SPM compared to their
corresponding common homozygous genotypes after
multivariable adjustment for age, sex, ethnicity, smoking,
and drinking [18]. When we performed similar analyses
stratified by SPM type, the effect modification of the
three polymorphisms was not pronounced for tobacco-
related SPMs, compared to non-tobacco-related SPMs
(data not shown). Furthermore, no significant difference
in SPM risk was observed, when SPMs were stratified
by smoking status at the time of diagnosis of index
SCCHN (ever versus never smokers) (data not shown).
We also did not observe pronounced effects of each
polymorphism of p21 and p27 on risk of SPMs at either
tobacco-associated sites or non-tobacco-associated sites
(data not shown).
Since each of three SNPs in p27 and p21 genes in cell
cycle regulation had a moderate effect on risk of SPM,
we then assessed the combined effect of all three SNPs
on risk of SPM in patients with index SCCHN as shown
in Table 3. In order to evaluate the joint effect of these
p27 and p21 polymorphisms on risk of SPM, we cate-
gorized all patients into four groups based on the num-
ber of variant genotypes they carried. We also
dichotomized patients into two groups: 1) a ‘no variant’
reference group and 2) a ‘variant’ group. We found that
patients who developed SPM were more likely to carry
the combined variant genotypes than those who
remained SPM-free (P < 0.001). Patients with variant
genotypes of three polymorphisms in p27 and p21
experienced a significantly reduced SPM-free survival
compared with those who had no variant genotypes
(log-rank, P < 0.001, Figure 1). We also found that the
SPM risk increased with the number of variant geno-
types, and the trend in risk was statistically significant in
a dose-response manner (P = 0.0002 for trend). Specifi-
cally, patients carrying 3 variant genotypes were
approximately 3 times more likely to develop a SPM
than those carrying no variant genotypes (HR, 3.0; 95%
CI, 1.6-5.7). Those patients who possessed either variant
allele (p27 109 G, p21 98 A or p21 70 T) were almost a
2.5 times more likely to develop a SPM (HR, 2.4, 95%
CI, 1.6-3.6) than those who had the combined p27 109
TT, p21 98 CC, and p21 70 CC common genotypes.
Discussion and conclusion
p21 and p27 are both G1-checkpoint CDK inhibitors
and have an approximately 42% amino acid homology at
the amino-terminal domain, which mediates inhibition
of CDK and interacts with various CDK complexes [19].
Alterations of expression or function of these two
Table 2 SPM risk associated with p27/p21 polymorphisms after index SCCHN
Genotypes Total
(No. = 1,292)
SPM-free
(No. = 1,172)
SPM
(No. = 120)
P
a HR (95% CI)
b
No. % No. % No. %
P27 T109G
TT (Ref.
c) 706 54.6 661 56.4 45 37.5
TG + GG 586 45.4 511 43.6 75 62.5 < 0.001 2.0 (1.5-3.1)
P21 C98A
CC (Ref.
c) 1,105 85.5 1012 84.6 93 77.5
CA + AA 187 14.5 160 13.6 27 22.5 0.009 1.7 (1.1-2.6)
P21 C70T
CC (Ref.
c) 706 54.6 661 56.4 45 37.5
CT + TT 586 45.4 511 43.6 75 62.5 0.004 1.7 (1.1-2.7)
ac
2 test for differences in the distribution of p21/p27 genotypes between the patients who developed SPM and the patients who did not
bAdjusted for age, sex, ethnicity, tobacco smoking and alcohol drinking in a Cox model
cRef. = reference group
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implicated in the etiologies and disease prognosis of
human malignancies [20]. In this study, we found that
each of three SNPs of p27 and p21 genes was associated
with a significantly increased risk of SPM in patients
with index SCCHN. We also observed significant asso-
ciations of the combined variant genotypes of three
polymorphisms with increased risk of SPM in patients
with index SCCHN, and the trend in risk was statisti-
cally significant in a dose-response manner. In addition,
the patients with either variant allele of three SNPs were
more likely to develop a SPM than the patients with no
variant genotypes. Approximately 15% of SCCHN
patients develop a SPM, a significant cause of posttreat-
ment morbidity and mortality for the diseases. Although
the diagnostic and therapeutic approaches, such as sur-
gery, radiotherapy, and chemotherapy, for SCCHN
patients have been improved, the poor prognosis for
SCCHN patients has not significantly improved, partly
because of the high frequency of SPM. Therefore, p27
and p21 polymorphisms may serve as a marker for
genetic susceptibility to SPMs after index SCCHN, and
for identifying high-risk subgroups of SCCHN patients
who might benefit from management of alternative
treatment and predictable patient outcome for an
improved survival and a better quality of life. Moreover,
identifying markers of risk for SPM among cancer survi-
vors would greatly enhance secondary prevention, which
is currently limited to rather simplistic clinical post-
treatment screenings.
The roles of both p27 and p21 proteins in modulating
cell cycle regulation has been well established. For
example, overexpression of p27 was reported to inhibit
CDK activation and entry into the S phase of the cell
cycle [21]. As p27 may be involved in pathways regu-
lated by both mitogenic and antiproliferative extrinsic
signals, the expression level of p27 was found to be
positively correlated with cell differentiation, and loss of
its function may subsequently contribute to tumorigen-
esis [22,23]. p27 is rarely mutated in human malignan-
cies; however, reduced expression of p27 was found to
be frequent in various types of cancers, such as gastric,
breast, prostate, and non-small cell lung cancers [24,25].
Furthermore, the reduced expression of p27 was also
found to be correlated with poor clinical prognosis in
head and neck cancers [26,27]. On the other hand, p21
protein is a downstream target of p53. In response to
DNA damage, increased expression of p21 following p53
activation leads to either cell-cycle arrest at the G1
checkpoint or apoptosis. Through inhibition of prolifer-
ating cell nuclear antigen-dependent DNA replication
and mismatch repair in vitro, p21 expression can sup-
press tumor growth [28]. Additionally, the overexpres-
sion of p21 may prevent mammalian cell proliferation
and inhibit all cyclin-CDK complexes, suggesting that
p21 is a universal inhibitor of cyclin-CDK complexes
[29]. Moreover, overexpression of p21 and the subse-
quent overall reduced CDK activity was found to be
associated with cell differentiation [30]. While somatic
mutations in p21 gene are rare in human malignancies
[31], reduced tumor expression of p21 has been
Table 3 SPM risk associated with p27/p21 polymorphisms after index SCCHN
No. variant genotypes Total
(No. = 1,292)
SPM-free
(No. = 1,172)
SPM
(No. = 120)
P
a HR (95% CI)
b
No. % No. % No. %
0 (Ref.
c) 606 46.9 572 48.8 34 28.3 < 0.001 1.0 (Ref.)
1 499 38.6 442 37.7 57 47.5 2.2 (1.4-3.4)
2 107 8.3 92 7.9 15 12.5 2.8 (1.5-5.3)
3 80 6.2 66 5.6 14 11.7 3.0 (1.6-5.7)
Trend P = 0.0002
No variants (Ref.
c) 606 46.9 572 48.8 34 28.3 < 0.001 1.0 (Ref.)
With variants 686 53.1 600 51.2 86 71.7 2.4 (1.6-3.6)
ac
2 test for differences in the distribution of combined variant genotypes between the patients who developed SPM and the patients who did not
bAdjusted for age, sex, ethnicity, tobacco smoking and alcohol drinking in a Cox model
cRef. = reference group
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Figure 1 Kaplan-Meier SPM-free survival curve stratified by
combined p21/p27 genotypes.
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Page 4 of 7associated with poor clinical prognosis [32]. Because
both p27 and p21 play important roles in cell cycle con-
trol regulation, it is suggested that alterations of p27
and p21 genes, such as above mentioned genetic poly-
morphisms, may, at least in part, reflect increased sus-
ceptibility of SCCHN patients to SPM. Recent studies
have indicated that SNPs of genes in cell cycle control
play an important role in carcinogenesis and may lead
to altered susceptibility to different cancers, including
primary SCCHN and their SPM [13,15,17,18,33-35].
Therefore, individuals carrying polymorphic CDK inhibi-
tors that may affect its protein function are likely to be
more susceptible to cancer.
Among p27 and p21 polymorphisms, the p27 T109G
polymorphism is within a region (amino acids 97-151)
physically interacting with the Jun activation domain-
binding protein 1, which triggers proteolytic degradation
of p27 [36]. Therefore, it is speculated that this poly-
morphism may affect p27 degradation. So far, the p27
T109G polymorphism has been reported to be asso-
ciated with risk and prognosis of prostate carcinoma
and breast cancer [14-16], whereas the results were not
consistent. These inconsistent results may be due to dif-
ferences between studies of cancer types, patient popula-
tion, and different risk factors for various types of
cancers. Other factors in the studies such as small sam-
ple size, inclusion of different ethnic groups in a single
study, gene-gene or gene-environment interactions, or
inadequate adjustment for confounding factors could
also cause the inconsistent results. The functional rele-
vance of this p27 polymorphism needs further investiga-
tions as p27KIP1 exerts anti- and pro-tumorigenic
activities [37]. Likewise, both p21 C98A and C70T poly-
morphisms are thought to cause p21 functional change,
because p21 C98A (at codon 31 in exon 2) may affect
the DNA-binding zinc finger motif [38], while p21
C70T (within the 3’ untranslated region in exon 3) lies
in a crucial region for cell differentiation, proliferation
and tumor suppression [39,40]. Moreover, several pre-
vious studies have reported that these p21 polymorph-
isms may affect protein expression and activity and may
have an effect on carcinogenesis [13,18,31]. However,
the exact mechanisms for these observations remain
unknown, and therefore, future studies on biological
functions of these polymorphisms are needed.
Although the current study had a relatively larger
cohort of SCCHN patients, there were few inherent lim-
itations as previously described [9,10,18]. Briefly, our
data on demographics, exposure, and clinical variables
for the cohort were collected prospectively, but SPM
outcome was recorded retrospectively. Because this
cohort included multiple ethnicities, our results might
not be generalizable to other ethnic populations. Addi-
tionally, because the time for SPM follow-up was limited
due to the majority of patients with stage III and IV
index cancer, these patients may have less opportunity
to develop a SPM, and patients with late stage disease
m a yb el o s tt of o l l o w - u po rd i er e l a t i v e l ys o o na f t e r
recruitment or diagnosis. Furthermore, a screening bias
for detecting tobacco-associated SPM or non-tobacco
associated SPM might also exist. Finally, lack of tumor
human papillomavirus (HPV) data and relatively low
SPM rate might bias our estimates of association. Pre-
sently, we have not collected enough HPV data in our
analysis for adjustment, and the low SPM rate might be
due to a high proportion of never-smoker patients and
use of strict criteria for SPM detection in this study. All
of these confounding factors will be considered in our
future studies.
In conclusion, our data suggest that p27 and p21 poly-
morphisms appear to alter individual susceptibility to
SPM in patients with index SCCHN and that the p27
(T109G) polymorphism may individually or in combina-
tion with p21 (C98A and C70T) polymorphisms to
increase risk of SPM in patients with an index SCCHN.
However, future larger and well designed studies with
longer follow-up time are needed to verify our findings.
Materials and methods
Study patients
In this study, patients with index SCCHN were recruited
through the Head and Neck Center at the University of
Texas M. D. Anderson Cancer Center between May
1995 and January 2007. Patients with SCCHN were typi-
cally followed and monitored through their treatment
and post-treatment courses with regularly scheduled
clinical and radiographic examinations. Details for
recruitment of study patients have been previously
described [9]. A SPM was carefully defined according to
the modified criteria of Warren and Gates [41]. Briefly,
SPMs were considered, if the second lesions had differ-
ent histopathologic types, or if they developed over 5
years after treatment for the index tumor, and/or clearly
separated by normal epithelium according to clinical
and radiographic assessment. Pulmonary lesions were
i n c l u d e da saS P M ,i ft h e yh a dan o n - s q u a m o u sh i s t o l -
ogy or if they were isolated squamous lesions over 5
years from index SCCHN and considered by both thor-
acic oncologist and thoracic surgeonas a SPM. If there
was discrepancy or difference in opinions regarding
recurrence or SPM, the second lesion was not consid-
ered a SPM but local recurrence. This study protocol
was approved by the institutional review board of the
University of Texas M. D. Anderson Cancer Center.
p27 and p21 genotyping
We used genomic DNA extracted from the buffy-coat
fraction of the blood samples to genotype p27 and p21
Wang et al. Molecular Cancer 2012, 11:17
http://www.molecular-cancer.com/content/11/1/17
Page 5 of 7polymorphisms as previously described [13,17]. We per-
formed the PCR analysis with a PTC-200 DNA Engine
Peltier thermal cycler (MJ Research, Waltham, MA) in
10 μl of PCR mixture. The PCR mixture contained
approximately 20 ng of genomic DNA, 0.1 mM dNTPs,
1× PCR buffer (50 mM KCl, 10 mM Tris HCl, and 0.1%
Triton X-100), 1.5 mM MgCl2,0 . 5u n i t so fT a qp o l y -
merase (Sigma-Aldrich, St. Louis, MO), and 2 pmol of
each primer. Specifically, for p27 V109G genotype, the
amplification conditions were 5 min of initial denatura-
tion at 95°C followed by 35 cycles of 15 sec at 94°C, 30
sec at 60°C, and 1 min at 72°C and a final 5-min step
at 72°C for final extension. A 454-base pair (bp) PCR
products were digested with restriction enzyme Bgl I at
37°C overnight (New England Biolabs, Beverly, MA),
and separated with 3% agarose gel containing ethidium
bromide. The genotype of codon 109 was determined
by a Gly allele with a fragment length of 76, 116, and
262 bp and a Val allele with fragments lengths of 76
and 378 bp. For p21 C98A and p21C70T genotypes,
the amplification conditions were 5 min of initial dena-
t u r a t i o na t9 5 ° C ;3 5c y c l e so f3 0sa t9 5 ° C ,3 5sa t5 5 °
C, and 45 s at 72°C; and a final 5-min extension step at
72°C. The conditions were the same for both genotypes
except that 30 cycles of 30 s at 59°C (annealing) and
30 sec at 72°C (extension) were used for p21C70T.
PCR products [496 base pairs (bp) for p21 C98A and
298 bp for p21C70T] were digested with the restriction
enzymes BsmAI (for p21 C98A) or PstI( f o rp21C70T)
(New England Biolabs, Beverly, MA) overnight at 55°C
(for BsmAI) or 37°C (for PstI) and separated with 3%
Metaphor gel containing ethidium bromide. The geno-
type of p21 C98A was identified by an A allele with
fragment lengths of 77, 92, and 238 bp and a C allele
with fragment lengths of 92, 165, and 238 bp. The gen-
otype of p21C70T was identified by a T allele with a
fragment length of 298 bp and a C allele with fragment
lengths of 173 and 125 bp.
We evaluated the genotyping results without knowing
the subjects with SPM or without SPM. For quality con-
trol purpose, we repeated at least 10% of random sam-
ples with a 100% concordance.
Statistical analysis
Statistical significance was determined by P values (P <
0.05) and all tests were two-sided. The Chi-squared tests
were used to exam differences in distribution of demo-
graphic, clinical, and genotyping variables between
patients who had SPM and those who did not. Kaplan-
Meier methods were used to determine SPM-free survi-
val between different risk groups. Both univariate and
multivariable Cox proportional hazards regression mod-
els were used for SPM assessment, and details in build-
ing the multivariable Cox models were described
previously [9]. The final Cox models were fully adjusted
for age, sex, ethnicity, and smoking and alcohol status
after a stepwise search strategy in developing the multi-
variable Cox models. Software utilized for analysis was
Statistical Analysis System software (SAS version 9.1.3;
SAS Institute).
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